A short peptide derived from the antisense homology box of Fas ligand induces apoptosis in anti-Fas antibody-insensitive human ovarian cancer cells

Apoptosis

Volumn 5, Issue 1, 2000, Pages 37-41

  Hayakawa, A ^a   Kojima, T ^a   Yokoyama, I ^a   Suzuki, H ^a   Tajiri, H ^b   Nakashima, I ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

Anti Fas antibody; Antisense homology box derived peptide; Apoptosis; Fas ligand; Ovarian cancer

Indexed keywords

ANTIBODY; DNA FRAGMENT; FAS ANTIGEN; PEPTIDE;

APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; OVARY CANCER; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY;

ANTIBODIES, MONOCLONAL; ANTISENSE ELEMENTS (GENETICS); APOPTOSIS; DNA FRAGMENTATION; FAS LIGAND PROTEIN; FEMALE; HUMANS; MEMBRANE GLYCOPROTEINS; NUCLEOSOMES; OLIGOPEPTIDES; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; SEQUENCE HOMOLOGY, AMINO ACID; TUMOR CELLS, CULTURED;

EID: 0034018814     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009633525205     Document Type: Article

References (25)

1. Owen-Schaub LB, Yonehara S, Crump W, Grimm EA. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol 1992; 140: 197-205.
2. Miyawaki T, Yonehara S, Taniguchi N, et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol 1992; 149: 3753-3758.
3. Wakahara Y, Wakahara F, Tomoda Y, et al. Combination effect of anti-Fas antibody and chemotherapeutic drugs in ovarian cancer cells in vitro. Oncology 1997; 54: 48-54.
4. Hayakawa A, Yokoyama I, Tajiri H, Okamoto T, Nakashima I. Protein kinase C-dependent anti apoptotic mechanism that is associated with high sensitivity to anti-Fas antibody in ovarian cancer cell lines. Cancer Letters 1999; 140: 113-119.
5. Enari M, Hug H, Nagata S. Involvement of ICE like protease in Fas-mediated apoptosis. Nature 1995; 375: 78-81.
6. Sato T, Irie S, Kitada S, Read JC. FAP-1: A protein tyrosine phosphatase that associates with Fas. Science 1995; 268: 411-415.
7. Suda T, Takahashi T, Goldstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
8. Schneider P, Bodmer JL, Tschopp J, et al. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J Biol Chem. 1997; 272: 18827-18833.
9. Starling GC, Bajorath J, Kiener PA, et al. Identification of amino acid residues important for ligand binding to Fas. J Exp Med 1997; 185: 1487-1492.
10. Fadeel B, Lindberg J, Achour A, Chodi F. A three-dimensional model of the Fas/Apo-1 molecule: cross-reactivity of anti-Fas antibodies explained by structural mimicry of antigenic sites. Interna Immunol 1998; 10: 131-140.
11. Bost KL, Smith EM, Blalock JE. Similarity between the corticotropin (ACTH) receptor and a peptide encoded by an RNA that is complementary to ACTH mRNA. Proc Natl Acad Sci USA 1985; 82: 1372-1375.
12. Baranyi L, Cambell W, Okada H, et al. The antisense homology box; a new motif within proteins that encodes biologically active peptides. Nature Med 1995; 9: 894-901
13. Takei M, Kojima T, Del Carpio CA. Analysis of sense and antisense peptide relationship in immunoglobulin IgE. In: Peptide Chemistry. Osaka, Japan: Protein Research Foundation, 1996: 217-220.
14. Blalock JE, Smith EM. Hydropathic anti-complementarity of amino acids based on the genetic code. Biochem Biophys Res Commum 1984; 121: 203-207.
15. Blalock JE. Complementarity of peptides specified by 'sense' and 'antisense' strands of DNA. Trends Biotech 1991; 6: 140-144.
16. Gorcs JJ, Gottschall PE, Coy DH, Arimira A. Possible recognition of the GnRH receptor by an antiserum against a peptide encoded by nucleotide sequence complementary to mRNA of a GnRH precursor peptide. Peptides 1986; 7: 1137-1145.
17. Knutson VP. Insulin-binding peptide: design and characterization. J Biol Chem 1988; 263: 14146-14151.
18. Moore GJ, Ganter RC, Flanklin KJ. Angiotensin "antisensepeptides": (-) messenger RNA complementary to human angiotensin II (+) messenger RNA encodes an angiotensin receptor antagonist. Biochem Biophys Res Commun 1989; 160: 1387-1391.
19. Kang CY, Brunk TK, Blalock JE, Kohler H. Inhibition of self-binding antibodies (autoantibodies) by a VH-denved peptide. Science 1988; 240: 1034-1036.
20. Pasqualini R, Chamone DF, Brentani RR. Determination of the putative binding sites for fibronectin on plateletglycoprotein IIb-IIIa complex through a hydropathic complementarity approach. J Biol Chem 1989; 264: 14566-14570.
21. Ghiso J, Saball E, Leoni J, Rostagno A, Frangione B. Binding of cystatin C to C4: the importance of sense-antisense peptides in their interaction. Proc Natl Acad Sci USA 1990; 87: 1288-1291.
22. Ruiz-Opazo N, Akimoto K, Herrera VLM. Identification of a novel dual angiotensin II/vasopressin receptor on the basis of molecular recognition theory. Nature Med 1995; 10: 1074-1081.
23. Eberle AN, Huber MJ. Antisense peptides: Tools for receptor isolation? Lack of antisense MSH and ACTH to interact with their sense peptides and induce receptor-specific antibodies. Receptor Res 1991; 11: 13-43.
24. Rasmussen UB, Hesch RD. On antisense peptides: the parathyroid hormone as an experimental example and a critical theoretical view. Biochem Biophys Res Commun 1987; 149: 930-938.
25. Root-Bernstein, RB. Amino acid pairing. J Theor Biol 1982; 94: 885-894.